In SOPHIA, the median progression-free survival (PFS) of patients treated with margetuximab and chemotherapy was 5.8 months compared to 4.9 months in patients treated with trastuzumab and ...

Margetuximab is under clinical development by MacroGenics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success ...